Ireland’s cancer clinical trials have saved the State about €6.5 million in drug costs over the past 12 months, according to Cancer Trials Ireland.
The charity’s figure is based on a sample of 38 cancer clinical trials and is presented as an estimate of avoided drug spending due to trial participation. One report frames the finding primarily as a cost-saving impact, while another also highlights participation shortfalls.
Irish Independent says participation in clinical trials is below the national target, pointing to missed opportunities for patients to take part. RTE similarly focuses on the financial benefit, while also citing the charity’s reported savings. Together, the coverage focuses on both the budgetary value of trials and the challenge of increasing enrolment to meet planned goals.